TKPHF OTC
Takeda Pharmaceutical Company Limited
1W: +3.1%
1M: +13.2%
3M: +17.8%
YTD: +33.5%
1Y: +41.6%
3Y: +49.0%
5Y: +73.0%
$41.15
-0.07 (-0.17%)
Pre-Market: $40.11 (-1.04, -2.52%)
Weekly Expected Move ±8.1%
$35
$38
$41
$45
$48
Credit Risk of going bust: lower than 78% of companies Debt: 32.7% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.99 (down 98%), Takeda Pharmaceutical Company Limited would be worth roughly what it owes.
Total debt $31.29B against a stock market value of $64.51B.
Distance to default 9.14 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $17.29B (short-term plus half of long-term), stock volatility 21.6%; Altman Z'' 1.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $31.29B against a stock market value of $64.51B.
Distance to default 9.14 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $17.29B (short-term plus half of long-term), stock volatility 21.6%; Altman Z'' 1.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
📊 Key Metrics
TTM$4,627B
Revenue
+3.3% YoY
$181B
Net Income
+31.9% YoY
$700B
Free Cash Flow
-10.8% YoY
66.7%
Gross Margin
16.5%
Op. Margin
9.3%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE2.5%
ROA1.2%
ROIC2.8%
Valuation
P/E55.3
P/B1.3
EV/EBITDA0.0
Leverage
Debt/Equity0.65
Current Ratio1.14
Interest Cov.2.0x
Quality Scores
Piotroski F6/9
Altman Z—
Beneish M-2.34